Intuitive Expands Investment and Footprint in Europe
MWN-AI** Summary
Intuitive (NASDAQ:ISRG), a leader in minimally invasive care and robotic-assisted surgery, announced on March 2, 2026, the completion of its acquisition of the da Vinci and Ion distribution business from ab medica, Abex, Excelencia Robótica, and their affiliates. This strategic move extends Intuitive's direct operations into Europe, specifically Italy, Spain, Portugal, Malta, San Marino, and associated territories. The transition allows Intuitive to enhance customer support and expand access to advanced surgical technologies across these regions, thereby improving patient outcomes and reducing overall healthcare costs.
CEO Dave Rosa emphasized the significance of this acquisition, stating that it marks an important step in the company’s mission to provide effective minimally invasive care in Europe. The integration of roughly 250 employees from the acquired businesses into Intuitive’s European commercial team, led by Senior Vice President Dirk Barten, signifies a commitment to driving innovation and enhancing the patient and care team experience.
As of December 31, 2025, there were over 470 da Vinci surgical systems installed in the Southern European region. The Ion endoluminal system, which is designed for advanced procedures, has recently launched in Italy and Spain, underscoring Intuitive's focus on broadening its technological footprint.
Intuitive remains dedicated to its vision of less invasive, more effective care, supporting healthcare professionals with cutting-edge technologies that allow for precise and minimally invasive surgical interventions. The company is committed to continuous innovation to meet the evolving needs of patients and medical practitioners alike. Overall, this acquisition presents a significant growth opportunity for Intuitive in the European market, positioning it for leadership in robotic-assisted surgery well into the future.
MWN-AI** Analysis
Intuitive Surgical (NASDAQ: ISRG) has taken a significant step forward by acquiring the da Vinci and Ion distribution business from ab medica, Abex, and Excelencia Robótica. This strategic expansion into the European market enhances Intuitive's presence in key regions such as Italy, Spain, Portugal, and Malta, aligning with the growing demand for minimally invasive surgical technologies. As the company integrates approximately 250 new employees into its European commercial structure, investors should consider the implications of this acquisition for future growth.
The move not only increases Intuitive's operational agility but also positions the company to support healthcare providers more effectively, thereby potentially improving patient outcomes while lowering the cost of care. There are over 470 da Vinci surgical systems currently operational in Southern Europe, indicating a solid installed base that Intuitive can leverage for market expansion. Furthermore, the recent launch of the Ion endoluminal system in Italy and Spain signifies the company's commitment to diversifying its offerings in growing markets.
From an investment perspective, this acquisition could signify a bullish outlook on ISRG stock. Analysts should keep a close watch on how Well Intuitive integrates the new operations and retains key talent. Success in these areas can translate into stronger market performance, especially given that the minimally invasive care sector is projected to see sustained growth based on technological advancements and evolving healthcare practices.
However, potential investors should remain cautious about the risks outlined in Intuitive's forward-looking statements. Economic conditions, regulatory changes, and operational challenges may pose hurdles to realizing the anticipated benefits of this acquisition. Therefore, weighing these factors against the company's historical performance and growth prospects is essential for making informed investment decisions. Overall, Intuitive appears well-positioned to capture a larger share of the European healthcare market, but due diligence is essential.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SUNNYVALE, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the completion of its acquisition of the da Vinci and Ion distribution business operated by ab medica, Abex, Excelencia Robótica, and their affiliates.
The completion marks the formal expansion of Intuitive’s direct operations in Europe, enabling the company to support customers in a more agile and integrated way, and bring minimally invasive care to more patients across Italy, Spain, Portugal, Malta, San Marino and associated territories.
“Today marks an important step in our commitment to expanding access to proven, safe and effective minimally invasive care to more patients across Europe,” said Intuitive chief executive officer Dave Rosa. “Our direct presence means we are better positioned to meet the needs of our customers in these geographies as we drive forward our shared goals of improving patient outcomes, improving patient and care team experience, increasing access to minimally invasive care, and lowering the total cost of care.”
The da Vinci and Ion business of ab medica, Abex, and Excelencia Robótica is now wholly owned by Intuitive, and business operations are integrated into Intuitive’s European commercial and marketing organization, led by Senior Vice President and General Manager Dirk Barten.
“Intuitive is entering a new chapter, building on more than two decades of introducing and scaling access to our technology across Southern Europe,” said Barten. “We are excited to welcome approximately 250 employees to the Intuitive team as we commence our direct operations, and together continue driving innovation in service of patients, care teams, and healthcare professionals.”
There is a combined installed base of more than 470 da Vinci surgical systems in Italy, Spain and Portugal as of December 31, 2025. The Ion endoluminal system was recently launched in Italy and Spain.
About Intuitive
Intuitive (NASDAQ:ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic-assisted surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most.
About da Vinci Surgical Systems
There are several models of the da Vinci surgical system. The da Vinci surgical systems are designed to help surgeons perform minimally invasive surgery and offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels, and forceps) that are designed to help with precise dissection and reconstruction deep inside the body.
For more information, please visit the company’s website at www.intuitive.com.
Important Safety Information
For product intended use and/or indications for use, risks, cautions, and warnings and full prescribing information, visit https://manuals.intuitivesurgical.com/market. For summary of the risks associated with surgery and bronchoscopy refer to www.intuitive.com/safety.
Forward-Looking Statements
This press release contains forward-looking statements which relate to expectations concerning matters that are not historical facts. Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “can,” “could,” “should,” “would,” “targeted,” “potential,” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are necessarily estimates reflecting the judgment of Intuitive’s management and involve a number of risks and uncertainties that could cause actual results or impacts on its operations, financial performance, and business position to differ materially from those suggested by the forward-looking statements.
These forward-looking statements include, but are not limited to, statements related to integration of acquired companies, businesses, and assets, research and development of products and services, manufacturing and distribution of products, integration of products, obtaining of necessary regulatory approvals, technical and other performance of products and services, and making products and services available to more patients and health care professionals.
These forward-looking statements should be considered in light of various important factors and involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, performance, or achievements of Intuitive, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements include, among others, the risk that the anticipated benefits of the acquisition may not be fully realized or may take longer to realize than expected, difficulties in retaining key employees or maintaining relationships with customers, suppliers and other business partners of the acquired business, economic conditions in the geographic markets in which we operate, changes in governmental regulations, regulatory approval priorities, resources, and timelines, regulatory enforcement priorities, governmental investigations and civil litigation, and other factors discussed in Intuitive’s Annual Reports and other filings with relevant securities regulators.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those risk factors identified under the heading “Risk Factors” in Intuitive’s Annual Report on Form 10-K for the year ended December 31, 2024, as updated by its other filings with the U.S. Securities and Exchange Commission. Intuitive’s actual results may differ materially and adversely from those expressed in any forward-looking statements, and it undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.
Media ContactMegan Elliott, IntuitiveMedia.inquiries@intusurg.com
FAQ**
How does the acquisition of the da Vinci and Ion distribution business impact Intuitive Surgical Inc. ISRG's market position in Europe and its competitive advantage over other surgical technology companies?
What specific measures will Intuitive Surgical Inc. ISRG implement to ensure the integration of the 250 new employees from ab medica and other affiliates is successful and contributes to operational efficiency?
With over 470 da Vinci surgical systems in Italy, Spain, and Portugal, how does Intuitive Surgical Inc. ISRG plan to expand its market penetration and increase the adoption of the Ion endoluminal system in these regions?
Can you provide insights on how the acquisition aligns with Intuitive Surgical Inc. ISRG’s long-term vision of improving patient outcomes and lowering the total cost of care in the healthcare sector?
**MWN-AI FAQ is based on asking OpenAI questions about Intuitive Surgical Inc. (NASDAQ: ISRG).
NASDAQ: ISRG
ISRG Trading
0.09% G/L:
$488.68 Last:
576,719 Volume:
$493.95 Open:



